Standout Papers
- Atlas polínico de Andalucía Occidental (1987)
Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
2000 Standout
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
2004 Standout
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer
2002
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007 Standout
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
EGFR Antagonists in Cancer Treatment
2008 Standout
Pancreatic cancer
2004 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics
2017 Standout
Diet, microorganisms and their metabolites, and colon cancer
2016
Basis for effective combination cancer chemotherapy with antimetabolites
2000
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
2011
Molecular mechanisms of cisplatin resistance
2011 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis
2014 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study
2000
Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity
2002
Targeting multidrug resistance in cancer
2006 Standout
Chemotherapy and the war on cancer
2005 Standout
Cetuximab in advanced non-small cell lung cancer
2006
Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer
2013
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine
2005
Nasopharyngeal carcinoma
2015 Standout
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma
1994
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
2006
Death Receptor 5 and Bcl-2 Protein Expression as Predictors of Tumor Response to Gemcitabine and Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer
2003
Role of gemcitabine in cancer therapy
2005
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial
2000
5-Fluorouracil: mechanisms of action and clinical strategies
2003 Standout
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
2000 Standout
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
2004
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: An effective second-line regimen
1997
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
2002
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
1996
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
2002
Disclosure of competing financial interests and role of sponsors in phase III cancer trials
2005
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Interstitial Lung Disease in Lung Cancer
2005
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
2001
Anemia of Chronic Disease
2005 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Industry sponsorship and research outcome
2012 Standout
Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin
2001
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
2004
The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial
2004
Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
1999
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
2002
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
2003 Standout
Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer
2002
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2
2005
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non–Small-Cell Lung Cancer
2002
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
2002
Human Neuroblastoma Cells Trigger an Immunosuppressive Program in Monocytes by Stimulating Soluble HLA-G Release
2007
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
2007
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
2002
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma
2002
Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group
2008 Standout
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
2007 Standout
Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review
2000
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
2000
Contribution of Dexamethasone to Control of Chemotherapy-Induced Nausea and Vomiting: A Meta-Analysis of Randomized Evidence
2000
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Clinical utility of plasma Epstein‐Barr virus DNA and ERCC1 single nucleotide polymorphism in nasopharyngeal carcinoma
2015
Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer
1999
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
2002
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
2003 Standout
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
2001
Pharmacogenetic Assessment of Toxicity and Outcome After Platinum Plus Taxane Chemotherapy in Ovarian Cancer: The Scottish Randomised Trial in Ovarian Cancer
2007
Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs.
2010
Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
2007
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Industry sponsorship and research outcome
2017 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of I. Barneto being referenced
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: A Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study
1998
Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer
1990
Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC)
1998
Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma
1999
Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity
1998
Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
2015
Single nucleotide polymorphisms and outcome in docetaxel–cisplatin-treated advanced non-small-cell lung cancer
2004
Prevention of Highly Emetogenic Chemotherapy-Induced Vomiting: A Double Blind, Randomized Crossover Study to Compare Pancopride (LAS 30451) and Pancopride plus Dexamethasone
1995
Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
1999